LISATA THERAPEUTICS, INC. Files 8-K

Ticker: LSTA · Form: 8-K · Filed: Jan 23, 2025 · CIK: 320017

Sentiment: neutral

Topics: sec-filing, 8-k, listing

Related Tickers: LSTA

TL;DR

LSTA filed a standard 8-K, confirming Nasdaq listing. No major news.

AI Summary

On January 22, 2025, LISATA THERAPEUTICS, INC. filed an 8-K report. The filing indicates that the company's common stock is registered and traded on The Nasdaq Capital Market under the trading symbol LSTA. The report does not disclose any specific material events or transactions.

Why It Matters

This 8-K filing serves as a notification to the SEC and investors that LISATA THERAPEUTICS, INC. is maintaining its reporting obligations. It confirms the company's listing on the Nasdaq Capital Market.

Risk Assessment

Risk Level: low — This filing is a routine procedural report and does not contain information that would immediately impact the company's risk profile.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing?

This 8-K filing is a Current Report filed by LISATA THERAPEUTICS, INC. to report information deemed of material importance to shareholders, as required by the SEC.

What is the trading symbol for LISATA THERAPEUTICS, INC. common stock?

The trading symbol for LISATA THERAPEUTICS, INC. common stock is LSTA.

On which exchange is LISATA THERAPEUTICS, INC. common stock traded?

LISATA THERAPEUTICS, INC. common stock is traded on The Nasdaq Capital Market.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is January 22, 2025.

Does this filing disclose any specific material events or transactions?

No, this filing does not disclose any specific material events or transactions beyond confirming the company's reporting status and stock exchange listing.

Filing Stats: 585 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-23 16:02:42

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 22, 2025, Lisata Therapeutics, Inc. (the "Company") issued a press release announcing preliminary cohort A data from the ongoing Phase 2 ASCEND trial (the "ASCEND Data") evaluating certepetide with standard-of-care chemotherapy in metastatic pancreatic ductal adenocarcinoma. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. A copy of a slide presentation that the Company will use at investor and industry conferences and presentations is attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. Exhibit No. Description 99.1 Press Release, dated January 22, 2025 99.2 Lisata Therapeutics, Inc. Corporate Presentation, dated January 22, 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President and Chief Executive Officer Dated: January 23, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing